Clinical Impact of New Data From ACG and DDW

Expert commentary from Raymond K. Cross, MD, MS, on management of moderate to severe ulcerative colitis, as reported to Clinical Care Options (CCO)

Raymond K. Cross, MD, MS Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Released: December 14, 2020 Expired: December 13, 2021

Experts discuss current best practice for choosing among biologics and other therapeutics for patients with moderate to severe ulcerative colitis from CCO

Anita Afzali, MD, MPH, FACG Millie D. Long, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Released: November 13, 2020 Expired: November 12, 2021

Introduction

Moderate to Severe UC

Why TNF Inhibitors?

Beyond TNF Inhibitors

Safety

Individualizing Treatment

Summary

CCO slides: current best practice for choosing among biologics and other JAK inhibitors for patients with moderate to severe ulcerative colitis

Expert video from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease

Uma Mahadevan, MD William Sandborn, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Released: November 13, 2020 Expired: November 12, 2021